News for Healthier Living

Sotagliflozin Outperforms Dapagliflozin for Reducing Salt-Sensitive Hypertension and Kidney Injury in Rats

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney-protective effects. In the kidney, SGLT2 reabsorbs approximately 97% of filtered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1 reabsorbs the remainder in the S3 segment. In research conducted in rats, investigators found that dual inhibition of SGLT1 and SGLT2 more effectively reduces salt-sensitive hypertension and kidney injury than SGLT2 inhibition alone. The findings will be presented at ASN Kidney Week 2025 November 5-9.

November 7, 2025


November 21 2025

November 20 2025

November 19 2025

November 18 2025

November 17 2025

November 16 2025

November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025

November 10 2025

November 9 2025

November 8 2025

November 7 2025